Pacylex Pharmaceuticals is a Canadian oncology company in Phase 2 with a highly differentiated cancer therapy, zelenirstat (PCLX-001), a first in class, once-per-day oral medication that completely regresses leukemias and lymphoma tumors in animals. Zelenirstat inhibits modification of membrane-associated proteins at the root of cancer signaling in leukemia and lymphoma. It also inhibits oxidative phosphorylation in cancer cells causing cell death. Phase 1 safety, PK, and drug exposure results with zelenirstat in 24 Non Hodgkin lymphoma (NHL) and solid tumor patients showed no dose limiting toxicities and drug exposure sufficient to initiate a Phase 2a expansion study in B-cell NHL as well as a study at MD Anderson in acute myeloid leukemia (AML) patients. Zelenirstat for AML received Orphan and Fast Track designations and IND clearance.